ReviewIndian heart journal2024
Dyslipidemia in diabetes.
Review in Indian heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Pooled it
- Evaluating the effects of seed oils on lipid profile, inflammatory and oxidative markers, and glycemic control of diabetic and dyslipidemic patients: a systematic review of clinical studies.Frontiers in nutrition · 2025Pooled it
- Article
- Prevalence and determinants of dyslipidemia among residents of Kurdistan Region of Iraq; a community-based study.BMC research notes · 2026Article
- Beyond Glucose: Palmitic Acid Influences VEGFA-VEGFR2 Angiogenic Signaling in Müller Glial Cells.International journal of molecular sciences · 2026Article
- Review
- Relationship between triglyceride glucose-waist circumference and depressive symptoms in Chinese older adults: The China health and retirement longitudinal study.Brain, behavior, & immunity - health · 2026Article
- Multi-Omics Analysis of a Spontaneous Type 2 Diabetes Model inInternational journal of molecular sciences · 2026Article
- Risk factors and nomogram for gallbladder stones in patients with type 2 diabetes mellitus: a retrospective study based on LASSO regression.Frontiers in endocrinology · 2026Article
- Diagnostic Model for Obesity and Type 2 Diabetes Mellitus Based on Feature Selection from Fatty Acids, Amino Acids, and Clinical Characteristics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Starch Biopolymer Functionalized withCurrent drug delivery · 2026Article
- Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia.Cardiology and therapy · 2025Article
- Comparative evaluation of the antidiabetic potential of three varieties ofToxicology reports · 2025Article
- Enhanced Sensitivity to Tramadol in Diabetic Neuropathic Pain Compared to Nerve Compression Neuropathies: A Population PK/PD Model Analysis.CPT: pharmacometrics & systems pharmacology · 2025Article
- Hypertriglyceridemia-Induced and Alcohol-Induced Acute Pancreatitis-A Severity Comparative Study.Diagnostics (Basel, Switzerland) · 2025Article
- Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk.Nutrients · 2025Review
- Detection of asymptomatic coronary artery disease among patients with type 2 diabetes mellitus using treadmill test.Bioinformation · 2025Article
- Glycemic control modifies LDL-C-DKD risk: a U-shaped association in well-controlled type 2 diabetes.Frontiers in nutrition · 2025Article
- Therapeutic potential ofFrontiers in pharmacology · 2025Article
- The Impact of Dyslipidemia on the Clinical Profile of Patients With Uncontrolled Diabetes.In vivo (Athens, Greece)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk factors for dyslipidaemia. Non-pharmacological management of dyslipidaemia is important and includes modification in the diet, increase in physical activity and efforts to reduce weight. Statins remain the mainstay of pharmacotherapy for dyslipidaemia in diabetes. Due to the small dense LDL, even patients with diabetes who have normal LDL cholesterol, achieve reduction in cardiovascular risk with statin therapy. Those patients who do not achieve acceptable LDL reductions with statin alone can be treated with combination therapy of ezetimibe with statins. Many novel therapies have also emerged such as bempedoic acid and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. The targets for LDL cholesterol depend upon the patients underlying cardiovascular risk category. The use of pharmacotherapy for lowering triglycerides in patients with mild to moderate hypertriglyceridemia and diabetes is still a matter of debate. Proper management of dyslipidaemia is critical component of treatment of diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.